All In MedTech

FDA Clearance Tracker · P930014

ACRYSOF (R) UV ABSORBING INTRAOCULAR LENSES

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 22, 1994 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 22, 1994

Approved

Time to decision

573 days

Received May 28, 1993. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P930014
Device name
ACRYSOF (R) UV ABSORBING INTRAOCULAR LENSES
Applicant location
Fort Worth, TX
Received
May 28, 1993
Decided
Dec 22, 1994
Decision
Approved
Supplements
161 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

Approval for the ACRYSOf® Models MA60BM and MA30BA Ultraviolet-Absorbing Acrylic Foldable UV-Absorbing Posterior Chamber Intraocular Lenses (IOLs). These devices are indicated for replacement of the human lens to achieve visual correction of aphakia in patients 60 years of age and older when extracapsular cataract extraction or phacoemulsification are performed. These lenses are intended for placement in the capsular bag.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code HQL. The earliest in FDA's data is K771933, decided Jan 26, 1978.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.